Navigation Links
Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts

New hires bring over 25 years of life sciences marketing experience to Cyntellect

SAN DIEGO, Jan. 15 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis and manipulation systems, announced today that it has appointed Dr. Stella Redpath as Director of Product Marketing for the company's Cell Health product line and Dr. Baggi Somasundaram as Product Marketing Manager for the company's cell purification product line.

"The extensive marketing and product management experience in the life sciences research market of Drs. Redpath and Somasundaram, particularly in the cellular bioassay and analysis markets, will accelerate the commercialization of Cyntellect's products for applications in biopharmaceutical cell line development, cell line development for drug discovery and research, and key applications utilizing stem cells and primary cells and for Cell Health applications," said David Burns, Cyntellect's VP Sales & Marketing and Chief Operating Officer. "We are very pleased to add the caliber and extensive experience of both Stella and Baggi to the Cyntellect commercial team."

Prior to joining Cyntellect, Dr. Redpath was a senior marketing manager at Millipore Corporation, where she led the predictive toxicology and high content analysis programs. She has also held business and sales positions at GE Healthcare, in the Advanced Systems Business Unit, and at Ciphergen Biosystems where she was Instrumentation Product Manager. Dr. Redpath was a Research Fellow in the Department of Immunology at the Scripps Research Institute (TSRI), and earned a Ph.D in Molecular Immunology in 1996 from the University of Cambridge, UK.

Prior to joining Cyntellect, Dr. Somasundaram was a Product Manager at BD Biosciences, where he managed the high content and confocal imaging platforms. He has also held business manager and sales positions at Atto Biosciences, and at PerkinElmer where he was the Applications Manager Live Cell Confocal Imaging Platform. Dr. Somasundaram was a Senior Research Fellow in the Department of Physiology, University of Cambridge, UK and at the Babraham Institute, Cambridge, and earned a Ph.D from the University of Wales, UK.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at

SOURCE Cyntellect, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cyntellect to Collaborate With the Burnham Institute for Medical Research
2. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
3. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. Codexis Appoints Singapore Laboratories Managing Director
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
11. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
Post Your Comments:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... . The Global ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):